TSBX: Turnstone Biologics Corporation Net earnings per share (EPS TTM)

Turnstone Biologics Corp. (TSBX) - corporate logo

Colossal R&D expenditures create a formidable barrier to entry in the sector, as reflected in the TTM net income per share trend, where the latest value is recorded as -2.02. Turnstone Biologics (TSBX) relies on inelastic demand in oncology, leveraging unique TIL lymphocyte selection. Simultaneously, the company is implementing robotic systems to accelerate clinical phases and automate sample preparation.

TSBX Turnstone Biologics Net earnings per share for the last 12 months (02/21/2024 - 08/24/2025)

Summary analytical data breakdowns for Turnstone Biologics (TSBX)

- share price and expert price forecast:
Stock Quotes Turnstone Biologics Corp.|TSBX - Fair Value Consensus
- market capitalization information:
Market Capitalization Turnstone Biologics|TSBX - Company Buyout Price
- business book valuation details:
Net Assets per Single Share Turnstone Biologics|TSBX - Company Net Assets|Market Value to Book Value Ratio turnstonebio.com|TSBX - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Turnstone Biologics|TSBX - Long-Term Debt to Capital|Short-Term Debt to Equity Turnstone Biologics Corp|TSBX - Company Aggregate Debt|Debt to Book Capitalization Ratio Turnstone Biologics Corp.|TSBX - Long-Term Debt|Company Current Liabilities Turnstone Biologics|Quick Liquidity Indicator turnstonebio.com
- earnings and multiples data:
TSBX - Profit After Payment of Taxes|Projected Future Earnings Turnstone Biologics|TSBX - Company Value to Net Income|Forward P/E Multiple Turnstone Biologics Corporation|TSBX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Turnstone Biologics Corp.|TSBX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Turnstone Biologics|TSBX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months turnstonebio.com|TSBX - Earnings per share trend in current year|Expected earnings per share growth for next year Turnstone Biologics
- revenue and sales details:
TSBX - Company Total Revenue|Company Future Sales Volume Turnstone Biologics Corporation|TSBX - Market Cap to Sales Volume|Forward Price-to-Revenue Multiple Turnstone Biologics Corp
Fundamental valuation:TSBX - turnstonebio.com
Flagship merchandise of Turnstone Biologics Corporation

Exclusive patents for TIL-cell selection create a sustainable market barrier for Turnstone Biologics (TSBX). This metric is calculated as net income divided by the average number of shares, which offsets the impact of share issuances. Investors utilize this calculation to assess the business's actual ability to generate cash flow. This trend allows them to filter out market noise and one-off transactions. By analyzing the earnings per share over a rolling year, one can determine the fundamental value of the business.

Main competitors

IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (Immunocore)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months zymeworks.com|Net earnings per share for the last 12 months tangotx.com (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics Inc (IOVA)|Net earnings per share for the last 12 months Immatics Corp IMTX|Xencor Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Corp CMPX|REPL - Earnings per share for the last twelve months|LYEL (lyell.com) - Earnings per share for the last 12 months|Innate Pharma S.A (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology, Inc. (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics)|Earnings per share for the trailing year IMMX|alxoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year CUE (Cue Biopharma)|PDS Biotechnology Corp (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings, Inc. - Earnings per share for the trailing year|MAIA (MAIABiotech.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Liminatus Pharma Inc.|Earnings per share for the last twelve months lavatherapeutics.com (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Tx (INTS) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Theriva Biologics - Earnings per share for the last four quarters|Gritstone Bio (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta, Inc. (KA)|Net earnings per share for the last 12 months NEXI|Net earnings per share for the last 12 months Vaccinex, Inc. (VCNX)|Earnings per share for the last twelve months Harpoon Therapeutics (HARP)